References:

1. Data on file. Novartis Pharmaceuticals Corporation.
2. ZOMETA Prescribing Information. Novartis Pharmaceuticals Corporation.
3. Aredia Prescribing Information. Novartis Pharmaceuticals Corporation.
4. Actonel Prescribing Information. Procter & Gamble Pharmaceuticals.
5. Boniva Prescribing Information. Roche Laboratories Inc.
6. Didronel Prescribing Information. Procter & Gamble Pharmaceuticals.
7. Fosamax Prescribing Information. Merck & Co., Inc.
8. Skelid Prescribing Information. sanofi-aventis US LLC.
9. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13.
10. Green JR, Mueller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
11. Rosen LS, Gordon D, Tchekmedyian NS, et al, on behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621.
12. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969.
13. Hatoum HT, Lin S-J, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438-1445.
14. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321.
15. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
16. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
17. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-2472.
18. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International Bone & Mineral Society Davos Workshops; March 9-14, 2008; Davos, Switzerland. Abstract 199.
19. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. Available at: http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf.
20. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907.
21. Harvey HA, von Reyn Cream L. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007;7(suppl 1):S7-S13.
22. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
23. Rosen LS, Gordon D,Kaminski M, et al. Zoledronic acid versus pamidronate in the Treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase II, double-blind, comparative trial. Cancer J. 2001;7:377-387
24. Saad F, Gleason DM, Murray R, et al, for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.
25. NIH Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis Handout on Health. Available at: www.niams.nih.gov/health_info_/bone/osteporosis/osteoporosis_hoh.asp?print=yes. Accessed September 24,2010.
26. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer. 1997;80(suppl 8):1538-1545.
27. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. Support Oncol. 2004;2:205-220.
28. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80 (suppl):1588-1594.
29. American Cancer Society. How Is Bone Metastasis Diagnosed? Available at:
    http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_bone_metastasis_diagnosed_66.asp.
30. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593-602.
31. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients wth hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
32. www.clinicaltrials.gov. Accessed November 6, 2009.
33. Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol. 2008;20:697-704.
34. Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr Treat Options Onc. 2003;4:239-246.
35. NIH What You Need to Know About Multiple Myeloma. Available at: http://www.cancer.gov/cancertopics/wyntk/myeloma.pdf.Accessed October 12, 2010.
36. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493.